Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TEPROTUMUMAB-TRBW Cause Product availability issue? 10 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Product availability issue have been filed in association with TEPROTUMUMAB-TRBW. This represents 0.2% of all adverse event reports for TEPROTUMUMAB-TRBW.

10
Reports of Product availability issue with TEPROTUMUMAB-TRBW
0.2%
of all TEPROTUMUMAB-TRBW reports
0
Deaths
2
Hospitalizations

How Dangerous Is Product availability issue From TEPROTUMUMAB-TRBW?

Of the 10 reports, 2 (20.0%) required hospitalization.

Is Product availability issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TEPROTUMUMAB-TRBW. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does TEPROTUMUMAB-TRBW Cause?

Muscle spasms (998) Fatigue (704) Tinnitus (524) Headache (443) Hypoacusis (430) Diarrhoea (408) Nausea (407) Blood glucose increased (401) Alopecia (390) Pain (344)

What Other Drugs Cause Product availability issue?

RUXOLITINIB (2,142) LISDEXAMFETAMINE DIMESYLATE (1,530) CERTOLIZUMAB PEGOL (1,381) VEDOLIZUMAB (636) AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (610) METHYLPHENIDATE (444) SECUKINUMAB (399) BIMEKIZUMAB-BKZX (364) LACOSAMIDE (359) BRIVARACETAM (324)

Which TEPROTUMUMAB-TRBW Alternatives Have Lower Product availability issue Risk?

TEPROTUMUMAB-TRBW vs TERAZOSIN TEPROTUMUMAB-TRBW vs TERAZOSIN\TERAZOSIN TEPROTUMUMAB-TRBW vs TERBINAFINE TEPROTUMUMAB-TRBW vs TERBINAFINE\TERBINAFINE TEPROTUMUMAB-TRBW vs TERBUTALINE

Related Pages

TEPROTUMUMAB-TRBW Full Profile All Product availability issue Reports All Drugs Causing Product availability issue TEPROTUMUMAB-TRBW Demographics